- The ADNAB ™ platform was developed and licensed to Sorrento exclusively by the Mayo Clinic
- Clinical studies using the ADNAB ™ platform are ongoing at the Mayo Clinic; and evaluate several advanced platform-generated outcomes: endometrial cancer, ovarian cancer, angiosarcoma, and B-Cell lymphomas
- The LS1681 Study is a Mayo-Initial Injection (IIT) test for recurrent or refractory B-cell lymphomas; and evaluates rituximab-ADNAB ™ (nab-paclitaxel nanoparticles not coated with rituximab)1
- Study MC1371 is a Mayo-Initiated-Trial Examiner (IIT) for various hard tumors; and has completed a dose increase rate2. To date, 9 endometrial and ovarian cancer patients, who had failed at least one previous regimen containing bevacizumab, were treated with bevacizumab-ADNAB ™ (nab-paclitaxel nanoparticles neo-covalently with bevacizumab).3
SAN DIEGO, February 08, 2021 (GLOBE NEWSWIRE) – Sorrento Therapeutics, Inc. has announced (Nasdaq: SRNE, “Sorrento”) today announced the establishment of ADNAB, Inc., a subsidiary that develops and commercializes the Mayo Clinic an advanced technology platform for the manufacture of antibody-drug conjugates (ADC), each with called ADNAB ™.
ADNAB ™ is a protective substitute of nanoparticle albumin-related drug products e.g., nab-paclitaxel, which is compatible with tumor-targeted monoclonal antibodies (mAb’s). The ADNAB ™ platform was developed by Svetomir Markovic, MD, Ph.D., and his research team at the Mayo Clinic. To date, Dr. Markovic’s team has created nine (9) ADNAB ™ candidates, including two (2) who are currently enrolling in an FDA-led human trial, initiated by inspector.
Using the G-MAB ™ Sorrento library of fully humanized monoclonal antibodies, the ADNAB ™ platform creates a broad package of product candidates targeted at melt and solid tumors. “We believe this platform has broad potential.” Said Henry Ji, Ph.D., Chairman and CEO of the newly formed ADNAB, Inc. “Our Vision is the reach of the highest to extend this platform to therapeutic areas outside of oncology; we have already introduced ADNAB ™ for autoimmune diseases. ”
Mayo Clinic physician Tom Habermann, MD, serves as Principal Investigator for the LS1681 Study, which evaluates rituximab-ADNAB ™ in recurrent / resuscitating B-cell lymphomas. Large recurrent B-cell lymphoma (RR DLBCL), which makes up about one-third of patients with DLBCL, remains a major cause of morbidity and mortality.
“I think this technology has the potential to be effective,” said Bradley J. Monk, MD, Professor of Gynecologic Oncology at the University of Arizona College of Medicine. “I am very pleased with the flexibility of this platform and want to see what we can do with a product aimed at CA-125,” said Dr Monk.
“The Mayo team have spent years refining this technology and now we have a colleague who will provide the resources necessary to accelerate and scale this program,” said Svetomir Markovic, MD, Ph.D. .D., Discovered and developed the ADNAB ™ platform technology.
“The published clinical trials testing this platform technology are encouraging and we look forward to working with the Mayo team on the ongoing and future clinical trials. Unsurprisingly, Sorrento and Mayo share the common goal of using this technology to develop multiple therapies for the potential benefit of cancer patients, ”said Ji.
ADNAB, Inc. expects to submit multiple IND this year; and to request a Breakthrough Therapy assignment from the FDA in both ovarian and endometrial cancer.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical-grade, antibody-centric, biopharmaceutical company developing new treatments to treat cancer and COVID-19. Sorrento’s multi-pronged, multifactorial approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ( “G-MAB leabharlann library”, clinical-stage immunosuppressive therapies (“CAR-T”, “DAR-T ™”), drug-antibody conjugates (“ADCs”), and clinical-stage oncolytic virus (Seprehvir ™ ”). Sorrento is also developing antiviral medications and vaccines against coronaviruses, including COVI-GUARD ™, COVI-AMG ™, COVI-SHIELD ™, Gene-MAb ™, COVI-MSC ™ and COVI-DROPS ™; and diagnostic test solutions, including COVI-TRACK ™, COVI-STIX ™ and COVI-TRACE ™.
Sorrento’s commitment to life-enhancing therapies for patients is also reflected in our effort to promote small molecules of first-class non-opioid pain control (TRPV1 agonist), resiniferatoxin (“RTX”), and SP-102 (10 mg, sodium viscous dexamethasone phosphate gel) (SEMDEXA ™), a novel, viscous gel formulation of corticosteroid that is widely used for epidural injection to treat lumbosacral radicular pain, or sciatica, and to replace ZTlido® (conventional lidocaine system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed IB level testing for cancer-related incontinence pain and level 1B testing in osteoarthritis patients. SEMDEXA in a Phase 3 test is important for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® approved by the FDA on February 28, 2018.
For more information, visit www.sorrentotherapeutics.com
Financial information
Mayo Clinic and Dr. Markovic have a financial interest in the technology mentioned in this press release. The Mayo Clinic will use any income it receives to support its nonprofit mission in patient care, education and research.
Forward-looking statements
This press release and any statements made for and during any presentation or meeting contain forward-looking statements relating to Sorrento Therapeutics, Inc., under safe harbor provisions of Section 21E of the Act. Private Security Literature Reform 1995 and subject to risks and uncertainties. which may cause actual results to be quite different from those intended. Forward-looking reports include reports on plans and timing for the development and commercialization of ADNAB technology for multiple therapies, including endometrial cancer, ovarian cancer, angiosarcoma and B-Cell lymphomas ; the initial test-of-opinion results of experiments initiated by an analyst to date; the ability for ADNAB technology to generate a broad portfolio of product candidates targeted at melt and solid tumors; plans to expand the ADNAB platform to other therapeutic areas, including autoimmune diseases; continue ongoing clinical trials and begin future trials at the Mayo Clinic; planned filming of multiple IND applications and plans to seek fracture treatment specification for STI-0201 in ovarian and endometrial cancers; and Sorrento’s research, clinical and commercial plans for ADNAB technology. There are risks and uncertainties that may cause our actual results to differ materially and materially from those reflected in our forward-looking statements, including, but they are not limited to: risks related to the technologies and expectations of Sorrento and its subsidiaries, affiliates and partners and cooperation with partners, including, but not limited to risks related to -connected to seeking regulatory approval for any antibody product candidates using ADNAB technology; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of problems or delays in obtaining regulatory approval; risks that the results of a clinical study do not meet any or all endpoints of clinical trials and that any data derived from such studies do not support a regulatory application or approval; risks that prior test results may not be repeated in future studies and tests; risks in the manufacture and supply of drug products; risks associated with reducing the experience of its employees, subsidiaries, affiliates and partners to assist Sorrento in implementing its cancer, anti-tumor and G-MAB strategies; risks associated with the global impact of COVID-19; and other risks outlined in Sorrento’s most recent quarterly reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year to 31 December , 2019, and subsequent quarterly Reports on Form 10-Q filed by the Securities and Exchange Commission, including the risk factors described in these films. Investors are cautioned not to rely heavily on these forward-looking statements, which speak directly from the date of this press release and we assume no responsibility for forward-looking statements. update any in this press release except as required by law.
Media and Investor Relations
Contact: Alexis Nahama, DVM (Corporate Development SVP)
Phone: 1.858.203.4120
Email: [email protected]
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
G-MAB ™, DAR-T ™, ANDAB ™, COVI-GUARD ™, COVI-AMG ™, COVI-SHIELD ™, Gene-MAb ™, COVI-DROPS ™, COVI-MSC ™, COVI-TRACK ™, COVI- TRACE ™ and COVI-STIX ™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA ™ is a trademark of Semnur Pharmaceuticals, Inc.
ZTlido® is a trademark of Scilex Pharmaceuticals Inc.
All other trademarks belong to their respective owners.
© 2021 Sorrento Therapeutics, Inc. All rights reserved.
1 https://clinicaltrials.gov/ct2/show/NCT03003546?term=Ls1681&draw=2&rank=1
2 https://clinicaltrials.gov/ct2/show/NCT02020707?term=mc1371&draw=2&rank=1
3 DOI: 10.1200 / JCO.2020.38.15_suppl.e18097 Journal of Clinical Oncology 38, no. 15_suppl